Advertisement

Topics

Pfizer Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin)

13:57 EDT 17 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
BESPONSA is the first and only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia Pfizer Inc. (NYSE:PFE) today announced that...

Other Sources for this Article

Pfizer Inc.
Media:
Sally Beatty, 212-733-6566
or
Investor:
Ryan Crowe, 212-733-8160

NEXT ARTICLE

More From BioPortfolio on "Pfizer Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...